A Phase 2 interventional study of placebo and varenicline in Schizophrenia, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2009-02-24.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing varenicline in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. Varenicline · Schizophrenia.
Among the 17 studies testing varenicline in Schizophrenia, this one is the 15th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 17 studies testing varenicline in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 24 across the 17 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
35 studies in Schizophrenia by Pfizer: none open now, none under way, none of them phase 3. Of 31 finished, 6 (19%) have results posted.
Among the 35 studies in Schizophrenia by Pfizer, this one is the 31st largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2009, is one of 10 in phase 2, and was the 21st registered.
Pfizer’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing varenicline in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 35 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic subjects who are receiving treatment with atypical antipsychotic medications.
A secondary objective is to evaluate the safety and tolerability of two doses of varenicline in symptomatically stable schizophrenic subjects who are receiving treatment with atypical antipsychotic medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: varenicline
Drug: varenicline
Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
Also known as: Chantix
Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
Also known as: Chantix, Champix
CNS Vital Signs Cognition Battery (CNS-VS-M) normed composite score
Time frame: screening, wk -1, baseline, wk 1,3,6
CNS-VS-M un-normed composite score
Time frame: screening, wk-1,baseline,wk1,3,6
CNS-VS-M un-normed and normed domain scores
Time frame: screening, wk-1,baseline, wk1,3,6
University of California San Diego Performance Skills Assessment Brief (UPSA-B) total score
Time frame: baseline, wk 1,3,6
Severity Item for Cognitive Impairment-Clinician and Patient Versions (SICI-CV; SICI-PV)
Time frame: baseline, wk6
Global Improvement in Cognition Clinician and Patient Versions (GIC-CV;GIC-PV)
Time frame: wk 1,3,6
Safety assessments, including adverse events, electrocardiographic assessments, neuropsychiatric assessments (performed weekly), physical exam, and laboratory measures
Time frame: weekly
No study locations are listed for this record.
The record gives a start of Mar 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline